| dc.description.abstract |
Aim: To assess the efficacy of bexagliflozin in reducing glycated hemoglobin (HbA1c) and the occurrence of side effects in patients with type 2 diabetes (T2DM).
Methods: We searched PubMed, Embase, Cochrane and ClinicalTrials.gov databases for placebo-controlled, randomized clinical trials until February 15, 2023. The primary outcome was change in HbA1c. We computed weighted mean differences (WMDs) for continuous outcomes and odds ratios (ORs) for binary endpoints, with 95% confidence intervals (CIs).
Results: A total of 6 studies and 3,111 patients were included, of whom 1,951 were prescribed bexagliflozin. Compared to placebo, bexagliflozin significantly reduced HbA1c levels (WMD -0.53%; 95% CI -0.75,-0.31), fasting plasma glucose levels (WMD -1.45 mmol/L; 95% CI -2.32,-0.57), systolic blood pressure (WMD -4.66 mmHg; 95% CI -6.41,-2.92), diastolic blood pressure (WMD -2.12 mmHg; 95% CI -3.94,-0.30), body weight (WMD -1.61 Kg; 95% CI -2.14,-1.07), and body weight in patients with a body mass index > 25 kg/m2 (WMD -2.05 Kg; 95% CI -2.78,-1.31). The proportion of patients who achieved HbA1c < 7% was higher in patients who received bexagliflozin as compared with placebo (OR 1.94; 95% CI 1.36-2.78). There were no significant differences between groups regarding side effects as hypoglycemia, genital mycotic infection, urinary tract infection, diarrhea, headache, náusea, polyuria, diabetic ketoacidosis, or all-cause mortality.
Conclusions: In this meta-analysis, the use of bexagliflozin was associated with improved clinical and laboratory measures in patients with T2DM compared to placebo, with a similar profile of side effects. These findings support the efficacy of bexagliflozin in the treatment of T2DM. |
pt_BR |
